Valuation: Novartis

Market Cap 291B 255B 234B 218B 414B 27,748B 420B 2,811B 1,093B 13,627B 1,094B 1,070B 47,025B P/E 2026 *
22.2x
P/E 2027 * 18.8x
Enterprise Value 324B 283B 260B 243B 460B 30,815B 466B 3,122B 1,213B 15,133B 1,215B 1,189B 52,222B EV / Sales 2026 *
5.69x
EV / Sales 2027 * 5.3x
Free-Float
91.66%
Yield 2026 *
2.76%
Yield 2027 * 2.85%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Chief Tech/Sci/R&D Officer 64 15/05/2022
Director TitleAgeSince
Director/Board Member 68 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+7.65%+55.77%+158.84% 1,082B
+3.57%+7.42%+69.09%+58.92% 633B
+3.99%+7.37%+36.87%+93.77% 461B
+3.86%+1.85%+31.30%+24.86% 339B
-0.56%+2.80%+39.13%+28.20% 301B
-1.54%+3.56%-25.96%-40.53% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+4.21%+6.00%+17.72%+70.33% 163B
+1.84%+2.75%-3.95%-33.70% 139B
Average +2.31%+4.67%+27.33%+47.69% 394.03B
Weighted average by Cap. +2.42%+5.62%+40.97%+79.22%

Financials

2026 *2027 *
Net sales 56.91B 49.77B 45.68B 42.64B 80.8B 5,418B 82.01B 549B 213B 2,661B 214B 209B 9,182B 60.37B 52.8B 48.46B 45.24B 85.71B 5,747B 86.99B 582B 226B 2,822B 227B 222B 9,740B
Net income 14.15B 12.38B 11.36B 10.61B 20.1B 1,347B 20.39B 137B 53.06B 662B 53.14B 51.98B 2,284B 15.74B 13.76B 12.63B 11.79B 22.34B 1,498B 22.67B 152B 58.99B 736B 59.08B 57.79B 2,539B
Net Debt 32.22B 28.18B 25.86B 24.14B 45.74B 3,067B 46.42B 311B 121B 1,506B 121B 118B 5,198B 28.72B 25.12B 23.05B 21.52B 40.78B 2,734B 41.38B 277B 108B 1,343B 108B 105B 4,633B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA